High bleeding risk patients treated with Medtronic PLC’s Resolute Onyx zotarolimus-eluting coronary stent and one month of dual-antiplatelet therapy in the Onyx ONE Clear trial showed low rates of cardiac death and myocardial infarction one year after the procedure.
ACC 2020: Medtronic’s Resolute Onyx DES Meets Goals In US/Japan High Bleeding Risk Patients
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.
